No price history available.
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHFm | 40 | 50 | 59 | 57 | 57 | 61 | N/A | N/A |
| Operating profit | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | CHFm | 0 | -14 | -0 | -7 | -28 | -16 | N/A | N/A |
| EPS reported | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | CHFm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | CHF | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1987 and headquartered in Tel Aviv, Israel, SHL Telemedicine Ltd. is a global provider specializing in the development and distribution of individual remote healthcare solutions across Israel, Europe, and other international markets. The company's extensive product line includes a variety of advanced electrocardiogram (ECG) devices designed for personal use: Smartheart, a mobile 12-lead ECG capable of identifying heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter; Cardio'B, a portable 12-lead ECG unit; and the Cardio Beeper 12/12, a handheld device that transmits full ECG readings to a monitoring center. Beyond cardiac monitoring, SHL offers a suite of other remote diagnostic tools, such as a central communication module for relaying medical data from various devices to its telemedicine centers, TeleWeight for trans-telephonic weight tracking, TelePress for remote blood pressure measurements, TeleBreather for assessing lung function, and the TelePulse Oximeter for measuring blood oxygen saturation and pulse rate. These telemedicine services and devices are delivered to subscribers via both telephonic and internet communication channels. The company caters to a diverse range of clients, including individual patients, health insurance providers, hospitals, clinics, medical practitioners, and other healthcare organizations. SHL Telemedicine is also engaged in key collaborative research efforts. It partners with the Mayo Clinic to evaluate the efficacy of its FDA-approved SmartHeart in reducing emergency department visits, re-hospitalizations, and major adverse cardiovascular events in post-heart attack patients over a 90-day period. Additionally, the company is working with the Hebrew University of Jerusalem and the Hadassah Medical Center to create an artificial intelligence tool designed to predict future life-threatening cardiac incidents based on 12-Lead ECG monitoring.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1987 and headquartered in Tel Aviv, Israel, SHL Telemedicine Ltd. is a global provider specializing in the development and distribution of individual remote healthcare solutions across Israel, Europe, and other international markets. The company's extensive product line includes a variety of advanced electrocardiogram (ECG) devices designed for personal use: Smartheart, a mobile 12-lead ECG capable of identifying heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter; Cardio'B, a portable 12-lead ECG unit; and the Cardio Beeper 12/12, a handheld device that transmits full ECG readings to a monitoring center. Beyond cardiac monitoring, SHL offers a suite of other remote diagnostic tools, such as a central communication module for relaying medical data from various devices to its telemedicine centers, TeleWeight for trans-telephonic weight tracking, TelePress for remote blood pressure measurements, TeleBreather for assessing lung function, and the TelePulse Oximeter for measuring blood oxygen saturation and pulse rate. These telemedicine services and devices are delivered to subscribers via both telephonic and internet communication channels. The company caters to a diverse range of clients, including individual patients, health insurance providers, hospitals, clinics, medical practitioners, and other healthcare organizations. SHL Telemedicine is also engaged in key collaborative research efforts. It partners with the Mayo Clinic to evaluate the efficacy of its FDA-approved SmartHeart in reducing emergency department visits, re-hospitalizations, and major adverse cardiovascular events in post-heart attack patients over a 90-day period. Additionally, the company is working with the Hebrew University of Jerusalem and the Hadassah Medical Center to create an artificial intelligence tool designed to predict future life-threatening cardiac incidents based on 12-Lead ECG monitoring.